Chinese Vaccine Makers are Ready to Start Vaccine Production
The Chinese vaccine makers, Sinovac Biotech Ltd. and Hualan Biological Engineering Inc., have completed the clinical trials. Their products are claimed to be effective in single doses for population from three to 60 years. Sinovac claims the annual capacity to produce up to 30 million doses of swine flu vaccine, Hualan claims 160 million doses [...]
Pandemic Vaccines: European Market Update
Global Pandemic Influenza Preparedness Market Forecast 2010-2015 - The report identifies issues and challenges for both the government as well as drug makers in addressing this market.
Four ‘mock-up’ vaccines developed by Baxter, GlaxoSmithKline and Novartis have already been approved in the European Union based on earlier data generated with the H5N1 virus strain, which is [...]
Flu Vaccine Produces Robust Immune Responses
New vaccine of Vical Incorporated against A/H1N1 pandemic influenza (swine flu) produced robust immune responses well above the accepted protection threshold in 100% of vaccinated mice and rabbits after a standard two-dose vaccine regimen. In addition, at least 75% of vaccinated animals achieved or exceeded the protection threshold after a single dose of vaccine. Vical [...]
Flu Vaccine Solution in Spain: VLP Technology
Novavax, Inc. announced initial agreement to license its proprietary, recombinant virus-like-particle (VLP) vaccine technology to ROVI Pharmaceuticals (Madrid: ROVI) of Spain. ROVI will use the VLP technology to create a comprehensive influenza vaccine solution for the Spanish government under a new 60 million euro program sponsored and led by the Spanish Ministry of Health and [...]
Protein Sciences Corporation Announced Production of H1N1 Swine Flu Vaccine
Protein Sciences Corporation (PSC) announced that it commenced manufacturing of a vaccine to protect humans against the H1N1 “swine flu” virus. The Company estimates that it can produce 100,000 doses this week and at least 100,000 doses per week thereafter. The vaccine, called PanBlok®, is made using PSC’s proprietary baculovirus and insect cell manufacturing technology. [...]
China’s First Influenza A (H1N1) Vaccine Order Goes to Sinovac
On June 14, 2009, Sinovac completed construction of the H1N1 virus seed bank necessary to produce a virus antigen and commenced production of the first batch of H1N1 vaccine. Sinovac expects to complete production of the first batch by the end of July.
Few days later Sinovac Biotech Ltd. announced the first order in [...]
Lethality of H1N1 Influenza Virus Increasing
As the World Health Organization raised its pandemic alert to phase 6, the top of its six-point scale, a new analysis released yesterday (June 10) of the latest peptide genomic data for the H1N1 influenza virus shows that the current global outbreak of H1N1 is increasing in its capacity for lethality. The new sequence data [...]
Baxter Advances to Full-Scale Production of A/H1N1 Vaccine
Baxter International Inc. (NYSE: BAX) announced today that it has completed testing and evaluation of the A/H1N1 influenza virus and is now in full-scale production of a commercial A/H1N1 vaccine using its Vero cell culture technology. Baxter received an A/H1N1 strain from the U.S. Centers for Disease Control and Prevention [a World Health Organization (WHO) [...]
US Influenza Vaccine Antigen and Adjuvant Orders for 2009 (H1N1)
Manufacturer
Bulk Vaccine Antigen
Oil-In-Water Bulk Adjuvant
Novartis
$150 million
$139 million
GlaxoSmithKline
$ 38 million
$144 million
Sanofi
$191 million
CSL Biotherapies
$180 million
MedImmune
$ 90 million
Total
$649 million
$283 million
HHS has contracted with these manufacturers that currently hold U.S. licenses for flu vaccine as part of the National Strategy for Pandemic Influenza. In May 2009, HHS issued new orders on these contracts to produce a bulk supply [...]
Influenza Vaccines for the new Virus Strain A (H1N1)
The first doses of influenza A (H1N1) vaccine could be available within five to six months after identification of the new virus. Prior to this date, small quantities of experimental vaccine will be made available to immunize volunteers in clinical trials to select the best vaccine formulations. Regulatory approval for the vaccines will be conducted [...]
